All AKR-001 Dose Groups Met Week 12 Efficacy Endpoints in NASH Phase 2a BALANCED Study
All AKR-001 dose groups met the primary endpoint, with statistically significant absolute reductions in liver fat of 12-14%All AKR-001 dose groups met the secondary endpoint of relative reduction in liver fat, with the 50mg and 70mg dose groups achieving >70% relative reductionsBlinded tolerability profile appears consistent with results from previous clinical trials evaluating AKR-001 in […]
